01 July 2019, Elbrit Life Sciences announced a 2 million USD
investment in setting up of its second manufacturing facility in Singtam,
East Sikkim.
Elbrit Life Sciences currently owns a manufacturing facility in
Pondicherry with a capacity to manufacture 2 million units of solid
dosage formulations per day. The new facility in Sikkim will have a
production capacity of 4 million units per day. The proposed facility will
be UKMHRA and EUGMP complaint. The planned factory will be a state
of the art infrastructure. The plant will majorly focus on manufacturing
finished solid dosage formulations for its domestic business as well as
export business. Elbrit Life Sciences chose Sikkim its destination for its
upcoming facility because of its emergence as a leading hub for
pharmaceutical manufacturing, favourable geographical conditions,
availability of skilled manpower and excellent co-operation from the state
government.
The firm currently manufactures and markets a wide range of branded
formulations across India with a major focus on cardiovascular, anti-
diabetic and neurology range and overseas markets with a major focus
on nutraceuticals. The company exports a wide range of nutraceutical
products to South East Asia, Russia and Latin American countries. As
the company looks to set a strong foothold in the domestic market and in
the international market, the new facility will play a vital part in the
company’s growth story.
The company’s new manufacturing facility in Sikkim will generate direct
employment for at least 250 people. This will be a part of the company’s
commitment to the Make In India initiative by the Honourable Prime
Minister of India Shri Narendra Modi ji.
The company aims the second manufacturing facility to be operational
by mid of 2020 and expects the regulatory approvals to be completed by
2021. The new facility will help the company to expand its global
footprint both in nutraceutical and pharmaceutical segments.
The company spokesperson also intimated that, the Elbrit Life Sciences
is currently manufacturing 65% of its domestic requirement and 80% of
its overseas requirement in its Pondicherry facility. With the addition of
the Sikkim facility, the company will look to manufacture 100% of its
requirement inhouse.
Elbrit Life Sciences is looking to diversify into Oncology, Gynaecology,
Paediatrics and Critical Care Nutraceuticals in the first half of next fiscal.
Speaking of new product launches, Elbrit Life Sciences has already
launched three new products in the year and three more additional
product launches are lined up in the second half of this fiscal. Elbrit Life
Sciences will constantly launch new products to meet the growing needs
of the Indian demographics.
The company spokesperson also added that the Elbrit Life Sciences is
adding more front line medical representatives both in India and in
overseas markets. By end of this financial year, Elbrit Life Sciences
plans to add an additional 500 front line sales executives in
unrepresented geographies domestically. Currently the company
employs more than 500 medical representatives across India and more
than 100 medical representatives in overseas markets. The company
aims to be among the top 100 firms in the domestic market by end of FY
21.
